AIM ImmunoTech Advances Phase 2 Pancreatic Cancer Trial with AstraZeneca

Event summary

  • AIM ImmunoTech's Phase 2 DURIPANC trial for metastatic pancreatic cancer, combining Ampligen and AstraZeneca's durvalumab, has outlined key milestones through 2027.
  • 18 subjects have enrolled so far, with full enrollment expected by July 2026.
  • Primary endpoint evaluation for Clinical Benefit Rate is scheduled for December 2026.
  • Secondary endpoints, including Progression-Free Survival and Overall Survival, will be assessed by June 2027.
  • Interim reports indicate promising Progression-Free Survival and Overall Survival, with no significant toxicity reported.

The big picture

AIM ImmunoTech's progress in the DURIPANC trial underscores the growing interest in immuno-oncology combinations for hard-to-treat cancers like pancreatic cancer. The trial's success could position Ampligen as a key player in the oncology space, potentially attracting larger partnerships or acquisition interest. The biotech sector has seen significant M&A activity around late-stage oncology assets, making AIM's strategic focus on pancreatic cancer a high-stakes bet for its shareholders.

What we're watching

Clinical Efficacy
Whether the combination therapy of Ampligen and durvalumab will demonstrate sustained clinical benefits in metastatic pancreatic cancer patients.
Regulatory Pathway
The pace at which AIM ImmunoTech can advance Ampligen toward a Phase 3 trial, given the promising interim data.
Strategic Partnerships
How the collaboration with AstraZeneca and Erasmus MC will influence future development and commercialization efforts.